Clinical utility of evoked potentials for programming subthalamic deep brain stimulation in Parkinsons disease.

Blake Hale, Anna Latorre, Lorenzo Rocchi, John Rothwell, Patricia Limousin

Abstract readReview

In one paragraph

Review in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Motor evoked potentials as markers of internal capsule current spread during deep brain stimulation for Parkinson's disease.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Blake HaleDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK. blake.hale@nhs.net.

Anna LatorreDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.

Lorenzo RocchiDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

John RothwellDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.

Patricia LimousinDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal subthalamic nucleus deep-brain stimulation (STN-DBS) for Parkinson's disease reduces motor symptoms without stimulating adjacent structures and causing side-effects. Fine-tuning STN-DBS using clinical evaluation is time-consuming and often requires multiple follow-ups. Electrophysiological recordings may enhance STN-DBS device programming for clinicians by providing objective evidence of neural pathway activation. This literature review critically evaluates evoked potentials as biomarkers of optimal STN-DBS and assesses potential integration into the device programming toolkit.

Identifiers

PMID41577688

DOI10.1038/s41531-026-01274-2

PMCPMC12929793

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.